Sanctuary Advisors LLC Buys 11,967 Shares of Novo Nordisk A/S (NYSE:NVO)

Sanctuary Advisors LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 4.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 304,856 shares of the company's stock after buying an additional 11,967 shares during the period. Sanctuary Advisors LLC's holdings in Novo Nordisk A/S were worth $26,016,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in NVO. Creative Planning increased its holdings in shares of Novo Nordisk A/S by 4.7% in the third quarter. Creative Planning now owns 294,799 shares of the company's stock valued at $35,102,000 after purchasing an additional 13,203 shares during the last quarter. Vontobel Holding Ltd. increased its holdings in shares of Novo Nordisk A/S by 23.3% in the third quarter. Vontobel Holding Ltd. now owns 12,138 shares of the company's stock valued at $1,445,000 after purchasing an additional 2,295 shares during the last quarter. First Citizens Bank & Trust Co. increased its holdings in shares of Novo Nordisk A/S by 6.5% in the third quarter. First Citizens Bank & Trust Co. now owns 17,025 shares of the company's stock valued at $2,027,000 after purchasing an additional 1,039 shares during the last quarter. AA Financial Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 13.9% in the third quarter. AA Financial Advisors LLC now owns 3,194 shares of the company's stock valued at $380,000 after purchasing an additional 389 shares during the last quarter. Finally, Verde Capital Management acquired a new position in shares of Novo Nordisk A/S in the third quarter valued at $1,320,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock traded up $0.88 during trading on Wednesday, reaching $83.21. The company's stock had a trading volume of 4,556,281 shares, compared to its average volume of 9,164,698. Novo Nordisk A/S has a 52 week low of $77.82 and a 52 week high of $148.15. The business's 50-day moving average price is $87.45 and its 200-day moving average price is $108.84. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $373.39 billion, a PE ratio of 25.29, a P/E/G ratio of 0.84 and a beta of 0.45.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. Novo Nordisk A/S's dividend payout ratio is currently 21.88%.

Analyst Upgrades and Downgrades

NVO has been the topic of several research reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. StockNews.com cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Sunday, December 29th. Finally, UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of "Moderate Buy" and a consensus target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.